BASF to Establish World-Scale Specialty Amines Plant in Nanjing, China
BASF will build a new world scale production plant to manufacture specialty amines at its existing wholly-owned site in the Nanjing Chemical Industry Park in China. The plant, which is scheduled to come on stream in late 2015, will have dimethylaminopropylamine (DMAPA) and polyetheramines (PEA) as the main products. With this new facility BASF will further strengthen its global production network. The new plant complements existing facilities in Germany and the US for DMAPA and PEA.
“BASF is a leading supplier of DMAPA and PEA globally, and this investment reflects our continued commitment to meeting the growing market demand in Asia Pacific,” said Sanjeev Gandhi, President of BASF’s Intermediates division. “Our ability to produce these products within the region will strengthen our supply reliability and better serve our customers with shorter lead times.”
“The investment is driven by the increasing consumption of personal care products by the growing middle class in China and in Asia,” said Dr Guido Voit, Senior Vice President, BASF Intermediates, Asia Pacific. “Additionally, the development in the construction, wind energy and coatings industries in China and other emerging countries in Asia will continue to drive demand for PEA.”
DMAPA is mainly consumed in the production of betaines, which are used as co-surfactants in personal care products like shampoo and body wash. DMAPA is also used in various other applications including dye-stuff intermediates, lubricant additives, electroplating, coupling agents for rubber and others.
PEA is an intermediate chemical for epoxy curing agents used in the production of plastics, polyurea coatings, adhesives, reaction injection moulding and wind blade composites. BASF offers polyetheramines under its Baxxodur brand.
BASF has manufacturing capacities for both products at its sites in Ludwigshafen, Germany, and in Geismar, Louisiana.
For further information, click here.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.